Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood blood.2024024861.

https://doi.org/10.1182/blood.2024024861

Published: 2024

Includes: Supplemental data

Journal Articles

Critical role of tripartite fusion and LBD truncation in certain RARA - and all RARG -related atypical APL

Blood (2024) 144 (14): 1471–1485.

https://doi.org/10.1182/blood.2024023883

Published: 2024

Includes: Supplemental data

Journal Articles

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Xian Zhang, Qinglong Wang, Ying Liu, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 6883.

https://doi.org/10.1182/blood-2023-185361

Published: 2023

Journal Articles

CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant

Xingyu Cao, Jianping Zhang, Yue Lu, Yanli Zhao, Deyan Liu, Min Xiong, Zhijie Wei, Jiarui Zhou, Xian Zhang, Junfang Yang, Hongxing Liu, Peihua Lu

Blood (2023) 142 (Supplement 1): 2155.

https://doi.org/10.1182/blood-2023-186030

Published: 2023

Journal Articles

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Hongxing Liu, Sr., Min Xiong, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 218.

https://doi.org/10.1182/blood-2023-179086

Published: 2023

Journal Articles

Partner Gene Associated Trinary Fusion and Orchestration of Multiple Molecular Events in Acute Promyelocytic Leukemia with Variant Rara Fusion Genes

Blood (2023) 142 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2023-187869

Published: 2023

Journal Articles

Advances in Acute Myeloid Leukemia Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification

Xue Chen, Lili Yuan, Yang Zhang, Fang Wang, Xiaoli Ma, Jiancheng Fang, Panxiang Cao, Yijun Liu, Zhixiu Liu, Ming Liu, Jiaqi Chen, Xiaosu Zhou, Mingyue Liu, David Jin, Peihua Lu, Hongxing Liu

Blood (2023) 142 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2023-187915

Published: 2023

Journal Articles

The Ingenious Multiple Efficacies of the Integrated Gene Fragment of Torque Teno Mini Virus in Orchestrating Promyelocytic Leukemogenesis Via Hijacking Rara

Blood (2023) 142 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2023-185426

Published: 2023

Journal Articles

Trinary Fusion with Ligand Binding Domain Castration Is Crucial in Rarg -Driven APL and Render Unresponsive to ATRA Via Allosteric Disability Mechanism

Blood (2023) 142 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2023-185483

Published: 2023

Journal Articles

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Xian Zhang, Lin Wang, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2023-185271

Published: 2023

Journal Articles

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Xingyu Cao, Jianping Zhang, Yue Lu, Yanli Zhao, Deyan Liu, Min Xiong, Ruijuan Sun, Zhijie Wei, Jiarui Zhou, Xian Zhang, Junfang Yang, Hongxing Liu, Sr., Peihua Lu

Blood (2023) 142 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2023-185696

Published: 2023

Journal Articles

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Jianqiang Li, Peihua Lu

Blood (2022) 140 (Supplement 1): 2369–2370.

https://doi.org/10.1182/blood-2022-158878

Published: 2022

Journal Articles

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Blood (2022) 140 (Supplement 1): 4733–4734.

https://doi.org/10.1182/blood-2022-164640

Published: 2022

Journal Articles

Short-Term Efficacy and Safety of Haplo Hematopoietic Stem Cell Transplantation for Refractory and/or Relapsed Leukemia

Wei Zhao, Min Xiong, Yanli Zhao, Man Chen, Hui Wang, Peihua Lu

Blood (2022) 140 (Supplement 1): 12961–12962.

https://doi.org/10.1182/blood-2022-166724

Published: 2022

Journal Articles

The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, Lefu Huang, Gailing Zhang, Yunchao Su, Xiaona Hu, Shulian Xia, Jingjing Li, Peihua Lu

Blood (2022) 140 (Supplement 1): 8884–8885.

https://doi.org/10.1182/blood-2022-168603

Published: 2022

Journal Articles

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Xing-yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jiarui Zhou, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Xian Zhang, Junfang Yang, Peihua Lu

Blood (2022) 140 (Supplement 1): 4802–4803.

https://doi.org/10.1182/blood-2022-166993

Published: 2022

Journal Articles

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang, Jingjing Li, Liyuan Qiu, Wengang Ge, Bo Pei, Jie Chen, Lu Han, Jiangtao Ren, Peihua Lu

Blood (2022) 140 (Supplement 1): 4566–4567.

https://doi.org/10.1182/blood-2022-165733

Published: 2022

Journal Articles

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu, Ying Liu, Junfang Yang, Xian Zhang, Xiao Yang, Hui Wang, Lin Wang, Qinglong Wang, David Jin, Jianqiang Li, Xiaojun Huang

Blood (2022) 140 (4): 321–334.

https://doi.org/10.1182/blood.2021014498

Published: 2022

Includes: Supplemental data

Journal Articles

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

Xian Zhang, Gailing Zhang, Wenqian Li, Yang Zhang, Tong Wang, Junfang Yang, Jingjing Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 3828.

https://doi.org/10.1182/blood-2021-149809

Published: 2021

Journal Articles

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 473.

https://doi.org/10.1182/blood-2021-147667

Published: 2021

NARROW

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Critical role of tripartite fusion and LBD truncation in certain RARA - and all RARG -related atypical APL

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

Partner Gene Associated Trinary Fusion and Orchestration of Multiple Molecular Events in Acute Promyelocytic Leukemia with Variant Rara Fusion Genes

Advances in Acute Myeloid Leukemia Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification

The Ingenious Multiple Efficacies of the Integrated Gene Fragment of Torque Teno Mini Virus in Orchestrating Promyelocytic Leukemogenesis Via Hijacking Rara

Trinary Fusion with Ligand Binding Domain Castration Is Crucial in Rarg -Driven APL and Render Unresponsive to ATRA Via Allosteric Disability Mechanism

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Short-Term Efficacy and Safety of Haplo Hematopoietic Stem Cell Transplantation for Refractory and/or Relapsed Leukemia

The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only